Every letter we have printed

Displacement is small for these quantities and not always negligible. Adding 2 mL of diluent to a vial containing a few milligrams of solid gives very slightly more than 2 mL of solution. It is a fraction of a per cent and it is worth knowing that the direction of the error is always the same.

Your rotation advice says site does not affect absorption in this class, and then says to rotate anyway. If absorption is unaffected, why bother?

Community-generated management advice is frequently sensible and occasionally not, and no mechanism exists to distinguish them. A publication cannot fix that and it can at least describe how the advice is generated, which is more useful than repeating it.

Adding a second medicine to manage the effects of the first is a real decision with its own consequences, and it is discussed far too casually in general forums. It belongs with a clinician who knows the whole picture, and this letter is not advice to anyone.

A tenfold error is the characteristic failure of decimal arithmetic under any circumstances, and every account of a miscalculation I have read in this context is a factor of ten. That is a signature and it points at where the safeguards should sit.

The hundred-unit convention is the source of more confusion than anything else in this subject, because the graduation is a volume marking that was designed for a different drug at a fixed concentration. On a syringe marked to a hundred units, one unit is a hundredth of a millilitre and nothing else. Everything downstream follows from that single sentence.

The recurring error I see is a factor of ten, and it is always a decimal place in the concentration step rather than a misreading of the syringe. That suggests the intervention is a sanity check on the concentration before anything is drawn, not more careful reading of graduations.

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.

I have been reading this department since the first issue and it remains the only coverage of this trade I would put in front of a colleague.

Your series has changed how I read a storefront and I would add one habit for other readers. Before looking at any mark, find the date. If there is no date anywhere on the page, the mark is decoration and the rest of the page should be read in that light.

A verified badge on a seller’s own page supports exactly one claim: that a document exists. It cannot support a claim about the lot in front of the buyer unless the badge resolves to a report identifying that lot, and almost none of them do.

Blind means the analyst does not know the origin. It does not mean the analyst does not know the expected answer, and for a common molecule at a common strength they will. That is a second blinding nobody attempts and it is not obvious it can be attempted.

I would like to know how often a blind programme has been unable to complete a purchase — order cancelled, payment refused, nothing delivered. Those are results, they are never published, and they may be the most informative data any programme collects.

Where somebody discontinued and later resumed, most datasets record only the first event. The resumption is either lost or counted as a new entry, and the resulting rates describe a population with no memory.

Reasons interact. Cost that would be tolerable alone becomes decisive alongside a tolerability issue that would also have been tolerable alone. Single-reason coding cannot represent this and almost all coding is single-reason.

Sample sizes in the withdrawal arms are typically a fraction of the initiation cohorts, which widens every interval in the interesting part of the study. Coverage tends to quote the point estimate from the smallest arm in the paper.

Every discussion of maintenance I read assumes the person has settled on one arrangement. In practice people change source, change schedule and change what they measure, often several times, and a phase described as steady is frequently nothing of the sort.

What would help most is a clear statement of which questions have been studied at what horizon, in one table. Your reference desk does something close to this and it is more valuable than another analysis piece.

A sample that arrives at a laboratory in an unlabelled tube tells the analyst nothing about where it came from, and the report can only ever describe what was in the tube. The certificate says the material is pure; it cannot say the material is yours.

I would like the retention policy printed on the certificate. A laboratory that keeps raw data for seven years and one that discards it after ninety days offer very different documents, and the difference only becomes visible at the moment you need to go back to it.

The composite test table you print as a model is unrealistic. No research supplier is going to run headspace GC and ion chromatography on every lot at these price points, and publishing an aspirational document as a benchmark just makes real certificates look worse than they are.

Your suggestion of a published lookup at the testing laboratory is the right answer and it is not a large piece of engineering. Report number in, issued or not issued out, with no further detail. It would end the recycled-document trade in the wider market without exposing any customer data at all.

The receptor’s structure was solved with several ligands bound and the resulting papers are freely readable. They explain a good deal that used to be described as empirical and they are cited almost nowhere outside the specialist literature.

Receptor reserve means that a large fraction of receptors can be unoccupied while the maximal response is still obtained, which undercuts every argument that reasons directly from occupancy to effect.

A note on species differences that catches people out. Receptor pharmacology established in rodent tissue does not transfer cleanly, and several of the older mechanistic claims in circulation rest on preparations that were never human. Your citation practice is better than most on this point.

Internalisation and recycling determine what a sustained exposure does over days, and almost all the published potency work is measured over minutes. The two timescales answer different questions and the shorter one is the one everybody quotes.

Grading scales designed for oncology are used in this literature and they fit poorly. A scale calibrated against life-threatening events compresses everything a person in these studies is likely to experience into its lowest two categories.

Discontinuation rates for adverse effects in the published trials are the most useful single figure in this whole subject, because they capture the point at which symptoms actually changed a decision. They are also considerably lower than the incidence figures that get quoted.

A short note on reporting. Where a study reports training volume, it should report it in a form somebody could reproduce: sessions, exercises, sets and progression. Most report a duration in weeks and nothing else.

Nothing in this area has been studied in the population that most reads about it, which is people acquiring material outside a clinical setting and training without supervision. Every figure is a read-across and should be labelled as one.

Turnover markers are cheaper, faster and more responsive than imaging, and they are collected in a minority of these studies. They answer a different question and they answer it inside a trial horizon.

Weight-bearing changes as mass changes, and the mechanical loading on the skeleton changes with it. Any bone finding in a mass-loss study is confounded by that mechanically, quite apart from anything pharmacological.

Absolute and relative statements point in opposite directions here and both are true. Lean mass falls in absolute terms and the proportion of the body that is lean can rise. Choosing which to headline is an editorial decision and it should be made visibly.

Reading these studies alongside your dossier work makes a point neither makes alone: the trial evidence describes a material of known provenance, and the market this publication covers does not guarantee that. Every extrapolation crosses that gap silently.

A design point rarely made: the withdrawal arm is the only place in this literature where anybody observes what happens after stopping under controlled conditions. However narrow the question, it is the only evidence of its kind and it deserves more careful reading than it gets.

Your taxonomy would benefit from a category for external events with no relation to the arrangement at all — a house move, a family illness, a period of travel. They are common, they are not failures of anything, and they are currently distributed across every other category.

I would like to see more attention to what people were doing before, not only after. A maintenance phase entered from a long stable period looks different from one entered after years of oscillation, and baseline history is almost never reported.

The tone is the achievement. Serious without being solemn, and sceptical without the sneer that usually accompanies it in coverage of this subject.

Composition of regained tissue is barely studied and is the question I would most like answered. Whether what returns resembles what was lost has practical consequences and there is very little data on it.

The physiology of regain after any weight loss is well described and predates all of this pharmacology by decades. Presenting it as a novel finding about these agents misplaces a body of work that would help readers understand what they are seeing.